A B S T R AC T
Background. Inactivating mutations of the calcium-sensing receptor (CaSR), of the G-protein subunit α11 (GNA11) and of the adaptor-related protein complex 2, sigma 1 subunit (AP2S1) genes are responsible for familial hypocalciuric hypercalcaemia (FHH). The aim of this study was to analyse prevalence and pathogenicity of CaSR, GNA11 and AP2S1 mutations in patients with an FHH phenotype and to compare them with a sample of patients with primary hyperparathyroidism (PHPT) in order to identify the most useful laboratory parameter for a differential diagnosis. Methods. Patients with an FHH phenotype were studied with polymerase chain reaction amplification and direct sequencing of the entire CaSR, GNA11 and AP2S1 coding sequences. Novel mutations were introduced in a Myc-tagged human wild-type (WT) CaSR cDNA-expressing vector, and functional assay was performed on human embryonic kidney cells evaluating expression and function of mutated proteins. Results. Among 16 FHH patients, none had an inactivating GNA11 or AP2S1 mutation while 3 (18.8%) carried a CaSR mutation and 10 (62.5%) at least one CaSR polymorphism. Within the latter group, 7 of 10 patients had more than one polymorphism (4.1 ± 2.1 per patient). Two novel CaSR mutations [c.2120A>T (E707V) and c.2320G>A (G774S)] were identified: the E707V mutation prevented CaSR expression (western blot), whereas the G774S mutation determined a reduced receptor sensitivity to calcium (IP 3 assay). PHPT patients showed significantly (P < 0.001) higher serum calcium, parathyroid hormone, urinary calcium and calcium-creatinine clearance ratio (CCCR) and significantly lower serum phosphate than FHH ones. Conclusions. FHH should be clearly differentiated by PHPT to avoid unnecessary surgery: CCCR could be a useful screening tool while genetic analysis should include the two novel CaSR mutations herein described. The role of multiple polymorphisms deserves further investigation in patients with an FHH phenotype.
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I N T RO D U C T I O N
The differential diagnosis of hypercalcaemia represents a relatively common task in clinical practice and includes mainly primary hyperparathyroidism (PHPT) and familial hypocalciuric hypercalcaemia (FHH). The discovery of inactivating mutations of the calcium-sensing receptor gene (CaSR, FHH1, chr 3q21.1) [1, 2] , of the G-protein subunit α11 (GNA11, FHH2, chr 19p13.3) [3] and of the adaptor-related protein complex 2, sigma 1 subunit (AP2S1, FHH3, chr 19q13.32) [4] has greatly changed the diagnostic work-up of hypercalcaemia: the identification of mutations in these genes is needed to avoid diagnostic mistakes with potentially serious consequences, such as unnecessary parathyroidectomy (PTX).
The CaSR is a G-protein-coupled plasma membrane receptor, which is widely expressed in the parathyroid gland and kidney tubule: it plays a key role in maintaining stable extracellular calcium concentrations through its ability to sense small increases in calcium concentrations and consequently inhibit parathyroid hormone (PTH) secretion and increase urine calcium excretion [5] . Inactivating mutations impairing CaSR expression or function determine a generalized resistance to high serum calcium concentrations and have been associated with hypercalcaemia [1] . Homozygous inactivating mutations result in neonatal severe hyperparathyroidism (NSHPT, MIM239200), which is characterized by extreme hypercalcaemia and skeletal changes of unremitting hyperparathyroidism [2] . Heterozygous loss-of-function mutations determine FHH1 (MIM145980), which is characterized usually by mild and asymptomatic hypercalcaemia (ionized calcium within 10% of the upper normal limit), a relatively low calcium excretion and a calcium-clearance to creatinineclearance ratio (CCCR) typically <0.01 [6] . In FHH, the resetting of calcium homeostasis to a mildly elevated level is not maintained by an increased PTH and the kidney participates in the genesis of hypercalcaemia by avidly reabsorbing calcium [6] .
The cloning of CaSR has provided a wealth of information about FHH and NSHPT pathophysiology, and overall >100 inactivating CaSR mutations were described in FHH and/or NSHPT [7] , including missense and nonsense mutations, insertions and deletion/insertions [8] . Several CaSR gene polymorphisms have also been identified, which proved to predict calcium concentrations even in the general population, in the absence of any other symptom or laboratory finding [1] .
Elevated extracellular calcium concentrations activate CaSR and in turn the G-protein subunit α11 (GNA11), resulting in accumulation of secondary messengers such as IP 3 . This eventually leads to a reduction of circulating PTH levels and to an increase of urinary calcium excretion. As inactivating mutations of GNA11 have been proven to alter the switch from guanosine diphosphate GDP to guanosine triphosphate (GTP), they decrease CaSR-induced signal transduction leading to type 2 FHH. On the other hand, activating mutations of GNA11 have been identified in a specific form of autosomal dominant hypocalcaemia (ADH2), producing the opposite effect on the protein function with an overall hyperactivation of the GDP-GTP switch and an increased CaSR sensibility to extracellular calcium [3] .
The AP2S1 gene codes for a key protein of clathrin-coated vesicles, which plays a pivotal role in CaSR internalization. Inactivating mutations of AP2S1 cause a decrease in the overall CaSR expression on cell membrane, thus reducing cellular sensitivity to extracellular calcium concentrations [4] .
While inactivating CaSR mutations account for ∼47-56% of FHH cases [9, 10] , the prevalence of GNA11 and AP2S1 mutations is based on scant data: two GNA11 mutations out of 11 subjects, one with a familial form (10%) [3] and 11 AP2S1 mutations out of 50 subjects, of which two as a familial form (22%) have been so far reported [4] .
As a molecular diagnosis might be possible in up to 70% of FHH patients, analysis of CaSR, GNA11 and AP2S1 genes is becoming the cornerstone for the management of hypercalcaemia, particularly for differential diagnosis between FHH and PHPT. The aim of the study was to analyse prevalence, type and potential pathogenicity of CaSR, GNA11 and AP2S1 mutations in a series of 16 patients with a clinical phenotype compatible with FHH, by analysing the whole coding sequences of these three genes. Moreover, we compared clinical and biochemical features of FHH patients with those of a cohort of PHPT patients in order to identify blood or urinary parameters that could be useful to clinically differentiate these two disorders before molecular diagnosis is performed.
M AT E R I A L S A N D M E T H O D S

Inclusion criteria
We included all patients with clinical and biochemical features compatible with FHH followed up at our Nephrology Outpatient Clinic >2 years (January 2010-December 2012). Patients were included as probands for FHH if they fulfilled all of the following criteria:
(i) Moderately elevated serum calcium: total calcium >10.0 mg/dL to <12 mg/dL or ionized calcium >5.4 mg/dL (ii) Low calcium-clearance to creatinine-clearance ratio (<0.02) by at least two independent urine samples and in the absence of any medication can modify renal calcium clearance (lithium, thiazide diuretics).
(iii) Normal or mildly elevated serum PTH (<219 pg/mL; normal range 17.3-73 pg/mL).
Patients with PHPT followed at our Nephrology Outpatient Clinic over the same period (January 2010-December 2012) were included if they had a histological diagnosis after PTX,
N e w C a S R m u t a t i o n s i n h y p e r c a l c e m i c s y n d r o m e s normocalcaemia following successful neck exploration, or, in cases of clinical contraindications to surgery, the presence of all the following criteria: serum PTH at least four times higher than normal (>292 pg/mL) at repeated assessments and calcaemia persistently >11.5 mg/dL with normal vitamin D levels. All patients gave their written informed consent to participate in the study and to undergo study procedures, including genetic analyses. The local ethical committee approved the study.
Molecular screening (Phase 1)
Peripheral blood was collected and deoxyribonucleic acid (DNA) extracted following a classic phenol-chloroform protocol. Molecular screening of the entire CaSR, GNA11 and AP2S1 coding sequences (18 exons-21 amplicons, including exonintron boundaries) was performed by polymerase chain reaction (PCR) amplification and direct sequencing. Mutations and polymorphisms were confirmed by sequencing in both directions on the original amplicon and on a different PCR product. Cell culture and transfection. Human embryonic kidney (HEK293) cells (ECACC) were cultured and transfected with WT or mutant vector using Lipofectamine 2000 Transfection Reagent (Invitrogen) as previously described [10, 11] .
Western blot. Forty-eight hours after transfection, total cell proteins were extracted in RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, 1%, Nonidet P-40, 0.1% sodium dodecyl sulphate (SDS), 0.5% sodium deoxycholate, pH 8.0) supplemented with one tablet/10 mL of PhosStop and complete ethylenediaminetetraacetic acid (both from Roche). Fifty micrograms were loaded onto a 6% SDS polyacrylamide gel, and proteins were electrotransferred to polyvinylidene difluoride membrane (Millipore, Billerica, MA), blotted overnight at 4°C with rabbit anti-Myc monoclonal antibody (Cell Signaling Technology, 1 : 800 in blocking buffer) and for 1 h at room temperature with the horseradish peroxidase-conjugated goat antirabbit IgG antibody (Cell Signaling Technology, 1 : 300 in blocking buffer) as secondary antibody. Membrane was stripped with Re-Blot Solution (Millipore) and reblotted with β-tubulin rabbit monoclonal antibody (Cell Signaling Technology, 1 : 1000 in blocking buffer) as loading control. IP3 assay. A modified protocol for measurement of IP1 [11] was set-up (IpOne Cell ELISA Assay Kit, CISBIO Bioassay, Paris). Sixty thousand HEK293 cells were seeded in 96 wells and transfected in eight replicates for each vector. After 48 h from the transfection, stimulation buffer (HEPES 10 mM, MgCl 2 0.5 mM, KCl 4.2 mM, NaCl 146 mM, Glucose 5.5 mM and LiCl 50 mM, pH 7,4) differently supplemented with two calcium concentrations (4 and 10 mM) was added for 1 h at 37°C, in quadruplicate for each vector. Then, the cells were lysed and the assay performed following the manufacturer's instructions. Controls included cells expressing the previously characterized inactivating (R66H) CaSR mutation and cells not transfected. The ODs at 450/620 nm were calculated as previously described [11] .
Clinical and biochemical comparison of FHH and PHTP (Phase 2)
The following serum and urine parameters were evaluated to compare the two subgroups of patients with FHH and PHPT: serum calcium, phosphate, PTH, urine calcium excretion, calcium clearance, calcium to creatinine clearance and calciumclearance to creatinine-clearance ratio (CCCR).
Statistical analysis
Data are expressed as mean ± standard deviation (SD) from triplicates experimental replicates and a P value of <0.01 was considered to be statistically significant. Comparisons between groups have been carried out with Wilcoxon test or χ 2 test as appropriate. All analyses were performed using SAS Release 9.1 (SAS Institute, Cary, NC).
R E S U LT S
Molecular screening
Overall, 16 patients with an FHH phenotype (64.1 ± 17.6 years, male: 10/16 = 62.5%) met the inclusion criteria and underwent molecular screening of the entire CaSR, GNA11 and AP2S1 coding sequences: 13 of them (13/16 = 81.3%) turned out to carry either CaSR mutations (n = 3) or polymorphisms (n = 10; Table 1 ). None of the patients carried an inactivating GNA11 or AP2S1 mutation, but molecular screening led to the identification of several previously identified polymorphisms (Table 2 ). Seven patients (43.8%) had more than one CaSR polymorphism, with a mean of 4.1 ± 2.1 (min-max range: 2-7) polymorphisms per patient; the most common ones were the exon 3 IVS3+260C>T and the exon 6 IVS5−89C>T polymorphism each found in four patients.
Most patients had moderate chronic kidney disease (CKD), with an estimated glomerular filtration rate (eGFR) of 54.9 ± 29.9 mL/min/1.73m 2 , hypercalcaemia (10.6 ± 0.35 mg/dL), hypocalciuria and a CCCR of 0.0062 ± 0.0048. Nephrolithiasis was relatively common (3/16 = 18.8%), particularly in patients with CaSR mutations (2/3 = 66.7%). Moreover, patients with an inactivating CaSR mutation were younger, had a better renal function and had a lower urinary phosphate-to-creatinine clearance ratio (although non-statistically significant, Table 1 ). The clinical features of patients with inactivating CaSR mutations are separately outlined in Table 3 .
Genetic analysis. The screening led to the identification of several polymorphisms (Table 2 ) and two coding variants (Table 2) 
Moreover, Patient #6 (novel mutation G774S, male, age at the diagnosis 70 years) had no children and his parents were deceased at the time of FHH diagnosis; he had two brothers and four sisters, one of whom had a mild hypercalcaemia with normal calciuria, but refused genetic testing. Patient #11 (novel mutation E707V, female, age at diagnosis 46 years) had two daughters with normal serum and urinary calcium; her parents were deceased at the time of diagnosis and her two brothers had normal serum calcium.
Western blot. With respect to the fully glycosylated 160 kDa and immature glycosylated 140 kDa species, the G774S mutant protein exhibited almost the same pattern as the WT CaSR, with a lower expression of the 140 kDa form. On the contrary in the E707V variant both forms were underexpressed and the 160 kDa expression was almost undetectable, as the R66H inactivating mutant control (Figure 1 ).
Cell ELISA assay. Consistently, the expression of the G774S mutant protein appeared similar to that of the WT, while the E707V was almost totally unexpressed ( Figure 2) . IP 3 assay. Taking into account that the EC 50 of the WT CaSR protein is in the range of 3.1-4.7 mM [11] , we deduced that the G774S variant impaired the signalling response of the receptor at basal level of calcium, while at higher level the activation is similar to that of the WT. Moreover, the E707V variants were characterized by a lower signalling activity for both calcium concentrations, as also compared with the R66H inactivating control (Figure 3 ). (Table 4) , higher mean calcium (11.9 ± 0.98 versus 10.6 ± 0.35), lower mean phosphate (1.89 ± 0.59 versus 2.79 ± 0.39) and higher mean PTH (433 ± 518 versus 116.9 ± 59.4). However, these variables significantly overlapped between the two groups. Urinary calcium and CCCR were higher in PHPT, with only two PHPT patients (12.5%) showing a CCCR of <0.001. As for clinical manifestations, nephrolithiasis and related surgery were less common in FHH than in PHPT patients (Table 4) .
D I S C U S S I O N
The aim of this study was to analyse the prevalence of CaSR, GNA11 and AP2S1 genetic variations in a cohort of Italian patients with FHH without hyperparathyroidism and to compare biochemical parameters of FHH and PHPT patients in order to identify the most useful discriminating clinical features. The main results are the relatively high frequency of CaSR alterations (mutations and multiple polymorphisms) among FHH probands and the identification of two novel inactivating CaSR mutations (E707V and G774S).
As to the first result, we found an unexpectedly high prevalence of patients carrying multiple CaSR polymorphisms: seven patients carry at least two polymorphisms, which may not be 'pathogenic' by themselves but might partially reduce CaSR activity when present in combination [7, 12, 13] ; however, the impact of multiple polymorphisms on FHH phenotype deserves more functional studies. Moreover, biochemical data of these probands' family members are currently available in only four families and show an autosomal dominant transmission of hypercalcaemia in two of them. Therefore, wider studies are necessary to extend genetic analyses to all family members in order to study the transmission of multiple FHH-related CaSR polymorphisms. In three patients, we found a specific polymorphism that has already been associated with hypercalcaemia (exon 7, A986S) [12] ; in two of them, it was associated with other polymorphisms, and in the third one with a CaSR mutation. Interestingly, the biochemical phenotype of patients without any polymorphism is not substantially different from those with a single polymorphism, suggesting that at least in part of these cases CaSR inactivation may be caused by an autoimmune mechanism, as widely reported in the past decade [14] [15] [16] .
Clinically, 4 out of 16 FHH-phenotype patients had previously suffered from one or more episodes of nephrolithiasis (two mutated patients, one patient with a single polymorphism and one patient without any genetic alterations), thus reflecting the well-known but complex relationship between CaSR mutations and nephrolithiasis. While on one hand activating mutations and polymorphisms such as R990G predispose to renal stones through hypercalciuria [17, 18] , on the other hand inactivating mutations could facilitate stone formation through hyperphosphaturia, impaired distal acidification and impaired dilution of urine. The latter two effects are an expected consequence of the inhibition of the CaSR physiological effects on proton secretion and vasopressin response at the collecting duct level [19] . However, further studies are needed to dissect the mechanisms of nephrolithiasis in patients with either activating or inactivating CaSR mutations.
Moreover, apart from stone-related mild and sporadic events, clinical symptoms and events were few or absent even in patients carrying an inactivating mutation, therefore, confirming the benign clinical course of FHH and hypocalciuric hypercalcaemia, especially if compared with PHPT.
As to the two novel CaSR mutations herein described, the mutation at residue 707 is located at the intracellular loop 2 (residues 701-724): only one naturally occurring inactivating mutation has been identified so far in this domain (W718X) [20] . The other novel mutation at the residue 774 is located into the transmembrane domain 5 (TM5, residues 770-792): four mutations of this domain have so far been associated with either ADH or FHH [21] [22] [23] [24] . In this study, we report 
--
functional assays showing that the two novel CaSR variants (E707V and G774S) impair the activity of the receptor, thus acting as inactivating CaSR mutations, in keeping with the clinical suspicion. Unfortunately, both affected individuals have relatively small pedigrees, in particular the parents of both probands were already deceased when FHH was diagnosed: as FHH does not have major clinical symptoms, its diagnosis relies on laboratory findings and thus cannot be excluded in an asymptomatic relative until serum and urinary calcium are measured, which is not possible in these two probands' parents. Therefore, we cannot determine if in these cases these mutations have been transmitted by one of their parents or if they arose 'de novo'. With regard to the GNA11 and AP2S1 genes, we found only eight patients with one or more GNA11 or AP2S1 polymorphisms and none with a known inactivating mutation (Table 2) . Even if GNA11-AP2S1 combined polymorphisms could possibly explain the hypocalciuric hypercalcaemia in patients without CaSR polymorphisms (such as Patient #7 and #9), functional studies are needed to confirm this hypothesis. F I G U R E 1 : Western blot of Myc-tagged CaSR on crude protein extract. The arrows indicate the different forms of the protein in terms of maturation: the fully mature glycosylated form is at 160 kDa, the immature non-glycosylated form is at 140 kDa. Lower panel: WT on the reference protein, β-tubulin. The assay showed that the E707V mutant protein is lower expressed as is the inactivating control (R66H) while the G774S protein appeared expressed similarly to the WT.
F I G U R E 2 : CaSR cell surface expression ELISA assay shows that the E707V mutant protein is not expressed at the plasma membrane while the G774S is subject to a normal trafficking process as the WT. Values shown are the means (±SEM) of three replicate experiments. *P < 0.05 compared with the WT.
Moreover, as 'non-pathogenetic' CaSR variants and singlenucleotide polymorphisms are very common in the general population and CaSR mutations have a higher prevalence in FHH with respect to those of GNA11 and AP2S1 taken together (67 versus 30%), the clinical suspicion of FHH should be confirmed as a first step by the sequencing of at least the CaSR gene.
Lastly, the comparison between FHH and PHTP patients showed several significantly different laboratory parameters, with a small area of overlap: this is true for serum calcium, phosphate, PTH and both urinary calcium and phosphate, but the best discriminating parameter was the CCCR.
The main limits of this study are its relatively small sample size and the lack of genetic analysis of family members, as we just started it.
In conclusion, in the presence of moderate hypercalcaemia, the discrimination between PHPT and FHH, including genetic analyses, is crucial to avoid useless PTX. Inactivating mutations of CaSR, GNA11 or AP2S1 should be considered even in sporadic cases, as 'de novo' mutation may be relatively common and family history may be silent. In a small cohort of patients with an FHH phenotype, we identified three CaSR mutations (two of them never reported before) and a high prevalence of multiple polymorphisms: our ongoing project is to extend the study to family members including non-affected ones, in order to analyse association between combined CaSR polymorphisms and FHH. Due to the low frequency of mutations, the impact of GNA11 and AP2S1 genetic analysis in the FHH patient management needs to be verified in larger studies and might be useful only in patients with a clearly defined FHH who do not carry any CaSR mutation. As to probands with multiple polymorphisms, current evidence suggests that many of these variants are not pathogenic, but we cannot exclude that some variant combinations exert an impact on the laboratory phenotype. On the other hand an autoimmune pathogenesis of CaSR inactivation could be responsible for FHH in cases without any polymorphism or with a single polymorphism. the '5 × 1000' voluntary contributions devolved to the Medical Genetics Laboratory, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo (FG), Italy. The sponsor (Italian Ministry of Health) did not directly participate to the study design or planning, nor in the collection or interpretation of data. The grant was awarded to carry out a research programme on the genetics of CaSR and CaSR-related genes.
AC K N OW L E D G E M E N T S
CO N F L I C T O F I N T E R E S T S TAT E M E N T
None declared.
R E F E R E N C E S
